TheraRadar

Pharma Intelligence, Simplified

Company Portfolios →

Shanghai Hengrui Pharmaceutical Co., Ltd.

31 active trials across 7 therapeutic areas

31
Active Trials
21
Phase 1
21
Phase 2
2
Phase 3
7
Therapeutic Areas
Portfolio Concentration: 71% of active trials in Oncology

Oncology

22 active / 24 total
Solid Tumor (Advanced)
13 active
15 total since 2015
NSCLC
3 active
3 total since 2015
Bladder Cancer
3 active 1 Ph3
3 total since 2015
Pancreatic Cancer
1 active
1 total since 2015
Esophageal Cancer
1 active
1 total since 2015
Hodgkin Lymphoma
1 active
1 total since 2015

Immunology

4 active / 7 total
Ankylosing Spondylitis
3 active 1 Ph3
3 total since 2015
Rheumatoid Arthritis
1 active
3 total since 2015
Atopic Dermatitis
0 active
1 total since 2015

Pain

1 active / 4 total
Acute Pain
1 active
3 total since 2015
Postoperative Pain
0 active
1 total since 2015

CNS

1 active / 3 total
Alzheimer's Disease
1 active
3 total since 2015

Respiratory

1 active / 3 total
Asthma
1 active
3 total since 2015

Urology

1 active / 3 total
Erectile Dysfunction
1 active
3 total since 2015

Cardiovascular

1 active / 2 total
Myocardial Infarction
1 active
1 total since 2015
Atrial Fibrillation
0 active
1 total since 2015

Click an indication to see competitive landscape (all sponsors in that indication).

Data: ClinicalTrials.gov (2015+)